Research progress and future prospects of small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs)

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are key agents in the treatment of type 2 diabetes mellitus (T2DM) and obesity. Small-molecule GLP-1RAs offer the advantage of oral administration while demonstrating efficacy comparable to that of peptide drugs. Despite synthetic challenges and solubility issues, compounds such as Pfizer’s PF-06882961 (Danuglipron), Eli Lilly’s LY3502970 (Orforglipron), and Hengrui Pharma’s HRS-7535 have shown potential to reduce glycosylated hemoglobin A1c (HbA1c) levels and body weight in Phase I-II trials, with mild to moderate gastrointestinal adverse effects, suggesting that they may be promising therapeutic options in the future.

Keywords

Type 2 diabetes mellitus / obesity / small-molecule glucagon-like peptide-1 receptor agonists / efficacy / safety

References

[1] Sun H,Karuranga S.IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.Diabetes Res Clin Pract2022;183:109119 PMCID:PMC11057359

[2] Kokkorakis M,Rhayem C.Emerging pharmacotherapies for obesity: a systematic review.Pharmacol Rev2024;Online ahead of print:

[3] Pantelis AG.Metabolic bariatric surgery in face of new anti-obesity medications-10 + 1 challenges.Metab Target Organ Damage2023;3:17

[4] Gasoyan H,Schulte R,Rothberg MB.Early- and later-stage persistence with antiobesity medications: a retrospective cohort study.Obesity2024;32:486-93

[5] American Diabetes Association Professional Practice Committee. 9. pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. Diabetes Care. 2025;48:S181-206. PMCID:PMC11635045

[6] Sidik S.Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective.Nature2023;619:19

[7] Choe HJ.Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists.Endocrinol Metab2021;36:22-9 PMCID:PMC7937847

[8] Griffith DA,Fortin JP.A small-molecule oral agonist of the human glucagon-like peptide-1 receptor.J Med Chem2022;65:8208-26 PMCID:PMC9234956

[9] Kadar EP,Kalgutkar AS,Steeno GS.Development of a sensitive LC-MS/MS assay to support human microdose study for an oral agonist of the GLP-1 receptor.Bioanalysis2024;16:545-55 PMCID:PMC11299791

[10] Chen L,Guo S.Discovery of novel 5,6-dihydro-1,2,4-triazine derivatives as efficacious glucagon-like peptide-1 receptor agonists.J Med Chem2023;66:7988-8010

[11] Tamura T,Joyashiki E.Identification of an orally active small-molecule PTHR1 agonist for the treatment of hypoparathyroidism.Nat Commun2016;7:13384 PMCID:PMC5120204

[12] Saxena AR,Esquejo RM.Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial.Nat Med2021;27:1079-87

[13] Ono R,Ichikawa Y.A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron (PF-06882961), an oral small-molecule glucagon-like peptide-1 receptor agonist, in Japanese adults with type 2 diabetes mellitus.Diabetes Obes Metab2023;25:805-14 PMCID:PMC10107991

[14] Saxena AR,Gorman DN.Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, phase 2 study comparing different dose-escalation schemes.Diabetes Obes Metab2023;25:2805-14

[15] Saxena AR,Brown LS.Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial.JAMA Netw Open2023;6:e2314493 PMCID:PMC10203889

[16] Pratt E,Liu R.Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.Diabetes Obes Metab2023;25:2634-41

[17] Pratt E,Liu R.Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.Diabetes Obes Metab2023;25:2642-9

[18] Frias JP,Eyde S.Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.Lancet2023;402:472-83

[19] Wharton S, Blevins T, Connery L, et al; GZGI Investigators. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389:877-88.N Engl J Med2023;389:877-88

[20] Ma X,Pratt EJ,Bhattachar SN.Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered orforglipron (LY3502970), a non-peptide GLP-1 receptor agonist.Diabetes Ther2024;15:819-32 PMCID:PMC10951152

[21] Wu J,Zhang Q.Safety, pharmacokinetics and pharmacodynamics of HRS-7535, a novel oral small molecule glucagon-like peptide-1 receptor agonist, in healthy participants: a phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose, and food effect trial.Diabetes Obes Metab2024;26:901-10

[22] Majzoub AM,Barnard A.Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH.Aliment Pharmacol Ther2021;54:880-9 PMCID:PMC8711247

[23] Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Committees and Investigators. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109-21.

[24] Mahaffey KW,Arici M.Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.Eur Heart J2024;Online ahead of print:

[25] Meissner WG, Remy P, Giordana C, et al; LIXIPARK Study Group. Trial of lixisenatide in early parkinson’s disease. N Engl J Med. 2024;390:1176-85.

[26] Hong CT,Hu CJ.Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease.J Biomed Sci2024;31:102 PMCID:PMC11539687